SLC5A2 and fatty liver disease: Recent studies further confirmed reductions in hepatic steatosis and fibrosis based on biomarkers such as controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and the FIB-4 index in patients who received SGLT2 inhibitors [20,21].